Investigating how BAX protein triggers cell death in cancer
Nanobodies for Dissecting the Structure and Function of Oligomeric BAX
This study is looking at a protein called BAX that helps control cell death, which is important for understanding how cancer cells survive longer than they should, and it aims to find ways to make those cancer cells more vulnerable.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10849662 on NIH RePORTER |
What this research studies
This research focuses on understanding the structure and function of the BAX protein, which plays a crucial role in the process of apoptosis, or programmed cell death. By creating a stable form of oligomeric BAX, the researchers aim to analyze its structure and how it interacts with other proteins involved in cancer. The study employs advanced techniques such as small-angle X-ray scattering and electron microscopy to visualize BAX and its behavior in cells. This could lead to insights into how cancer cells evade death and how to potentially overcome this resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with cancers that are known to involve dysregulation of the BAX protein and apoptosis, such as certain types of leukemia and lymphoma.
Not a fit: Patients with cancers unrelated to the BAX protein or those who are not experiencing issues with apoptosis regulation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for cancers that exploit the apoptosis pathway.
How similar studies have performed: Previous research has shown promising results in understanding apoptosis mechanisms, but this specific approach to studying oligomeric BAX is novel.
Where this research is happening
Boston, United States
- Harvard Medical School — Boston, United States (Active)
Researchers
- Principal investigator: Yu, Ellen — Harvard Medical School
- Study coordinator: Yu, Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.